The addition of immune checkpoint blockade, especially of anti-CTLA-4, greatly improves PLGA-MP-mediated cancer immunotherapy by a reinvigoration of antitumor immunity after cessation of microparticle-induced tumor-specific CTL response. This evidence concerns the gene CTLA4 and cancer.